Literature DB >> 26052911

Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

S Watanabe1, Y Waseda1, H Kimura1, H Takato1, K Ohata2, Y Kondo2, K Kasahara1, S Nakao2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26052911     DOI： 10.1038/bmt.2015.120

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.

Authors:  Navneet S Majhail; Charles A Schiffer; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2006-07       Impact factor: 5.742

2.  Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.

Authors:  Michael Stadler; Renate Ahlborn; Haytham Kamal; Helmut Diedrich; Stefanie Buchholz; Matthias Eder; Arnold Ganser
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

Review 3.  Obliterative bronchiolitis.

Authors:  Alan F Barker; Anne Bergeron; William N Rom; Marshall I Hertz
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.

Authors:  Attilio Olivieri; Michele Cimminiello; Paolo Corradini; Nicola Mordini; Roberta Fedele; Carmine Selleri; Francesco Onida; Francesca Patriarca; Enzo Pavone; Silvia Svegliati; Armando Gabrielli; Paola Bresciani; Roberta Nuccorini; Sara Pascale; Sabrina Coluzzi; Fabrizio Pane; Antonella Poloni; Jacopo Olivieri; Pietro Leoni; Andrea Bacigalupo
Journal:  Blood       Date:  2013-10-23       Impact factor: 22.113

6.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

Review 7.  Bronchiolitis obliterans following haematopoietic stem cell transplantation.

Authors:  A O Soubani; J P Uberti
Journal:  Eur Respir J       Date:  2007-05       Impact factor: 16.671

8.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

9.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Authors:  Attilio Olivieri; Franco Locatelli; Marco Zecca; Adele Sanna; Michele Cimminiello; Roberto Raimondi; Guido Gini; Nicola Mordini; Adriana Balduzzi; Pietro Leoni; Armando Gabrielli; Andrea Bacigalupo
Journal:  Blood       Date:  2009-04-29       Impact factor: 22.113

Review 10.  First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Authors:  Guoqing Wei; Shamudheen Rafiyath; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-11-26       Impact factor: 17.388
  10 in total
  2 in total

1.  Prevention of bronchiolitis obliterans-the realization of a hope?

Authors:  Marilia Cascalho
Journal:  J Heart Lung Transplant       Date:  2016-08-17       Impact factor: 10.247

2.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.